Treatment of superficial vein thrombosis with intermediate dose of tinzaparin: A real word cohort study – The SeVEN EXTension study

2021 ◽  
pp. 026835552094730
Author(s):  
Christos Karathanos ◽  
Dimitrios Chatzis ◽  
Panagiotis Latzios ◽  
Ioannis Papakostas ◽  
Konstantinos Goumas ◽  
...  
Keyword(s):  
Treatment Duration ◽  
Prolonged Treatment ◽  
Bleeding Complications ◽  
Superficial Vein ◽  
Duration Of Treatment ◽  
Vein Thrombosis ◽  
Superficial Vein Thrombosis ◽  
History Of ◽  
Deep Vein ◽  
Intermediate Dose

Background To assess the treatment of superficial vein thrombosis (SVT) with intermediate dose of tinzaparin in a setting of real world practice. Methods Prospective observational study of consecutive patients treated by vascular physicians in the private sector with tinzaparin (131 IU/Kg) once daily. Treatment duration was at the treating physician’s discretion. The outcomes of the study were symptomatic venous thromboembolism, extension of thrombus and bleeding complications. Results 660 patients were included and followed up for at least 3 months. Median duration of treatment was 30 days (14–120). History of prior deep vein thrombosis (HR 2.77; 95% CI= 1.18–6.49; p = 0.018) and current SVT above the knee (HR1.84; 95% CI = 1.33–3.53; p = 0.0002) were associated with prolonged treatment duration. Primary efficacy outcomes occurred in 20 (3%) patients. The median time to the event was 24 (6–92) days and was not related to treatment duration. Conclusions Tinzaparin at intermediate dose is an effective and safe treatment for SVT.

Tinzaparin in intermediate dose for the treatment of superficial vein thrombosis: Results from an observational multicenter study—SeVEN study

2017 ◽  
Vol 33 (9) ◽  
pp. 636-645 ◽  
Author(s):  
Athanasios Giannoukas ◽  
Christos Karathanos ◽  
Konstantinos Nikolakopoulos ◽  
George S Georgiadis ◽  
Chrisostomos Maltezos ◽  
...  
Keyword(s):  
Low Grade ◽  
Minor Bleeding ◽  
Superficial Vein ◽  
Duration Of Treatment ◽  
Once Daily ◽  
Vein Thrombosis ◽  
Superficial Vein Thrombosis ◽  
Deep Vein ◽  
Intermediate Dose

Objectives Low-molecular-weight heparins are recommended in the treatment of superficial vein thrombosis but with low grade of evidence. This study was conducted to assess the treatment outcomes of acute superficial vein thrombosis with intermediate dose of Tinzaparin. Methods Retrospective analysis of records from outpatients over a period of 16 months treated in seven centers with Tinzaparin 0.5 ml (10,000 anti-Xa IU) once daily for a period that was at the treating physician’s discretion. All the patients were followed up for at least 12 weeks. Results A total of 296 patients (189 females, mean age 57.4 years) were included. Two thirds of the patients (191/296, 64.5%) received treatment for approximately five weeks (mean 36.9 days) and the remaining (105/296, 35.5%) for a shorter period (mean 16.2 days). There was no difference in patients’ characteristics between the two treatment duration groups. The presence of thrombus above the knee and restricted daily activity were associated with longer period of treatment. Only one case with minor bleeding was observed. Recurrence of thrombosis over a 12-week follow-up period occurred in 6% (superficial vein thrombosis in 14 (4.7%), deep vein thrombosis in 3 (1%) and thrombus extension in the superficial veins in 1 (0.3%)). Recurrence was not related to the duration of treatment. Conclusions Intermediate dose of Tinzaparin was an effective and safe treatment for superficial vein thrombosis in the setting of real world practice. Location of thrombus and status of patients’ mobilization were associated with longer duration of treatment. Future prospective randomized studies are needed to corroborate these findings.

scholarly journals Increased risk of venous thrombosis in persons with clinically diagnosed superficial vein thrombosis: results from the MEGA study

Blood ◽  
2011 ◽  
Vol 118 (15) ◽  
pp. 4239-4241 ◽  
Author(s):  
Kirsten van Langevelde ◽  
Willem M. Lijfering ◽  
Frits R. Rosendaal ◽  
Suzanne C. Cannegieter
Keyword(s):  
Venous Thrombosis ◽  
Factor V Leiden ◽  
Population Based ◽  
Factor V ◽  
Superficial Vein ◽  
Vein Thrombosis ◽  
Increased Risk ◽  
Superficial Vein Thrombosis ◽  
History Of ◽  
Deep Vein

Abstract Superficial vein thrombosis (SVT) is regarded a self-limiting disorder, although the authors of recent studies showed that ultrasonographically diagnosed SVT is a precursor for venous thrombosis. We aimed to determine whether the same holds true for clinically diagnosed SVT and to what extent it is associated with thrombophilia in a population-based case-control study (ie, Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis). We found that a history of clinical SVT was associated with a 6.3-fold (95% confidence interval [CI] 5.0-8.0) increased risk of deep-vein thrombosis and a 3.9-fold (95% CI 3.0-5.1) increased risk of pulmonary embolism. Blood group non-O and factor V Leiden showed a small increase in SVT risk in controls, with odds ratios of 1.3 (95% CI 0.9-2.0) and 1.5 (95% CI 0.7-3.3), respectively. In conclusion, clinically diagnosed SVT was a risk factor for venous thrombosis. Given that thrombophilia was only weakly associated with SVT, it is likely that other factors (varicosis, obesity, stasis) also play a role in its etiology.

The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors

Blood ◽  
2013 ◽  
Vol 122 (26) ◽  
pp. 4264-4269 ◽  
Author(s):  
Rachel E. J. Roach ◽  
Willem M. Lijfering ◽  
Astrid van Hylckama Vlieg ◽  
Frans M. Helmerhorst ◽  
Frits R. Rosendaal ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Venous Thrombosis ◽  
Superficial Vein ◽  
Thrombotic Risk ◽  
Vein Thrombosis ◽  
Thrombotic Risk Factor ◽  
Key Points ◽  
Superficial Vein Thrombosis ◽  
History Of

Key Points Superficial vein thrombosis combined with an acquired thrombotic risk factor increases the risk of venous thrombosis 10- to 100-fold. If confirmed, these findings have important implications for the future prevention of venous thrombosis.

Recurrence of superficial vein thrombosis in patients with varicose veins

2016 ◽  
Vol 31 (7) ◽  
pp. 489-495 ◽  
Author(s):  
Christos Karathanos ◽  
Konstantinos Spanos ◽  
Vassileios Saleptsis ◽  
Aspasia Tsezou ◽  
Despina Kyriakou ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Regression Analysis ◽  
Logistic Regression Analysis ◽  
Varicose Veins ◽  
Gene Mutations ◽  
Ratio Method ◽  
Superficial Vein ◽  
Vein Thrombosis ◽  
Superficial Vein Thrombosis ◽  
History Of

Objective To investigate which factors other than history of superficial vein thrombosis (SVT) are associated with recurrent spontaneous SVT episodes in patients with varicose veins (VVs). Materials and methods Patients with a history of spontaneous SVT and VVs were followed up for a mean period of 55 months. Demographics, comorbidities, and thrombophilia screening test were analyzed. Patients were grouped according to the clinical–etiology–anatomy–pathophysiology classification. A multiple logistic regression analysis with the forward likelihood ratio method was undertaken. Results Thirteen patients out of 97 had a recurrence SVT episode during the follow-up period. All those patients were identified to have a thrombophilia defect. Protein C and S, antithrombin, and plasminogen deficiencies were more frequently present in patients without recurrence. Gene mutations were present in 38% in the nonrecurrence group and 77% in the recurrence group. After logistic regression analysis, patients with dislipidemia and mutation in prothrombin G20210A (FII) had an increased risk for recurrence by 5.4-fold and 4.6-fold, respectively. No deep vein thrombosis or pulmonary embolism occurred. Conclusions Dislipidemia and gene mutations of F II are associated with SVT recurrence in patients with VVs. A selection of patients may benefit from anticoagulation in the short term and from VVs intervention in the long term.

scholarly journals Superficial vein thrombosis and deep vein thrombosis – a comparison

2017 ◽  
Vol 13 (3) ◽  
pp. 311-316
Author(s):  
Zbigniew Krasiński ◽  
◽  
Krzysztof Aniukiewicz ◽  
Aleksandra Krasińska ◽  
Beata Krasińska ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Superficial Vein ◽  
Vein Thrombosis ◽  
Superficial Vein Thrombosis ◽  
Deep Vein

Venous thromboembolism

2020 ◽  
pp. 363-372
Author(s):  
Charlotte Frise ◽  
Sally Collins
Keyword(s):  
Risk Factors ◽  
Molecular Weight ◽  
Venous Thromboembolism ◽  
Low Molecular Weight Heparin ◽  
Superficial Vein ◽  
Mortality And Morbidity ◽  
Vein Thrombosis ◽  
Superficial Vein Thrombosis ◽  
Maternal Mortality And Morbidity ◽  
Deep Vein

Venous thromboembolism is a major cause of maternal mortality and morbidity. This chapter discusses thromboprophylaxis (including low-molecular-weight heparin and doses by patient weight), risk factors, deep vein thrombosis, pulmonary embolism, associated investigations, and management. Anticoagulants and bleeding while anticoagulated are both covered. Finally, superficial vein thrombosis in the first month postpartum is described.

scholarly journals Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis

Hematology ◽  
2017 ◽  
Vol 2017 (1) ◽  
pp. 223-230 ◽  
Author(s):  
Jan Beyer-Westendorf
Keyword(s):  
Clinical Decision ◽  
Superficial Vein ◽  
Compression Stockings ◽  
Surgical Interventions ◽  
Vein Thrombosis ◽  
Superficial Vein Thrombosis ◽  
Inflammatory Drugs ◽  
Deep Vein ◽  
Current Guidelines ◽  
Insight Into

Abstract The management of superficial vein thrombosis (SVT) is poorly defined and remains controversial overall. SVT has long been considered a benign, self-limited disease, but recent studies show that SVT carries a nonnegligible risk for recurrence, deep vein thrombosis, or pulmonary embolism. Current guidelines recommend the use of low-molecular-weight heparin or fondaparinux, but results of several surveys indicate that the majority of patients with SVT receive nonanticoagulant therapy only, which includes compression stockings or bandages, nonsteroidal anti-inflammatory drugs, topical application of heparin gel, or surgical interventions. However, several recent observational and interventional studies provide better insight into the optimal treatment of patients with SVT who are at different risks for thromboembolic complications. This educational review summarizes the available evidence and aims to provide practical guidance based on a clinical decision pathway.

Sign in / Sign up

Export Citation Format

Share Document